key: cord-0875708-ajarudz6
authors: Mathiasen, Victor Dahl; Oversoe, Stine Karlsen; Ott, Peter; Jensen-Fangel, Søren; Leth, Steffen
title: Recovery of moderate COVID-19 in a liver transplant recipient on continued immunosuppression: a case report
date: 2020-09-17
journal: Transplant Proc
DOI: 10.1016/j.transproceed.2020.09.007
sha: e2b6983824ac92315fa5b9ce44a2297167833db8
doc_id: 875708
cord_uid: ajarudz6

The global outbreak of severe acute respiratory syndrome coronavirus 2 has had an enormous impact on the world. It remains unclear to what extent liver transplant recipients should be considered at a higher risk of severe disease due to the limited data available. We describe a moderate course of COVID-19 in a patient who underwent a liver transplant two years earlier due to Budd-Chiari syndrome. The patient presented with malaise, headache, dry cough and fever for four days. Immunosuppressive therapy with tacrolimus and mycophenolate mofetil was continued throughout the course of infection, oxygen therapy was given for a single night and the patient gradually recovered with supportive care only. With this case report, we demonstrate that liver transplantation and immunosuppression is not necessarily associated with severe COVID-19 disease and emphasize that more information on this matter is urgently required. Withdrawal of immunosuppressive therapy could be associated with a higher mortality.

The global outbreak of severe acute respiratory syndrome coronavirus 2 (SARS- 

A 58-year-old female, who had a liver transplantation two years earlier due to On admission, the patient had a temperature of 38.6 °C, the blood pressure was 27 129/88 mm Hg, the heart rate 90 beats per minute, the respiratory rate 12 28 breaths per minute and the oxygen saturation 96% on ambient air. Her physical 29 examination was inconspicuous and subsequent biochemistry with only modest 30 signs of COVID-19 disease with C-reactive protein 9.8 mg/L (reference range < 31 8), creatinine 97 µmol/L (reference range, 45-90) and alkaline phosphatase 120 32 U/L (reference range, 35-105). Leukocytes were within normal ranges (reference 33 range, 3.5-10.0). White blood cell differential was not conducted initially. Liver 34 parameters were normal, and plasma-tacrolimus was within therapeutic range 35 (5.1 µg/L).

A supine chest radiograph was without evident infiltrates. Urinary dipstick was 37

normal. An oropharyngeal swab tested positive for SARS-CoV2 RNA using 

On day 11 after onset of symptoms, the patient was readmitted to the 10 9 /L. Over the following three days, biochemistry was only modestly affected, 

Chest radiograph was still without infiltrates. Sputum was culture negative and 62 PCR negative for Mycoplasma pneumoniae and Legionella pneumophila DNA.

After three days, day 14 after onset of symptoms, the patient improved, 64 meropenem was discontinued as bacterial superinfection was unlikely, immunosuppressive therapy was still continued and the patient was sent home 66 to self-isolation. 

COVID-19 pandemic: Its impact on liver disease 211 and liver transplantation

SARS-CoV-2 in Denmark: A nationwide cohort. medRxiv 2020.05.24

COVID-19: Abnormal liver function tests

COVID-19: consider cytokine storm 268 syndromes and immunosuppression

Clinical and immunological features of severe and 271 moderate coronavirus disease 2019

COVID-19 in long-term liver 273 transplant patients: preliminary experience from an Italian